Samsung Biologics logo. (provided by Samsung Biologics)Diagnosis kit stocks are rising in the stock market on the 29th as concerns about the re-spread of Corona 19 due to the new mutation ‘Omicron’ grow. In particular, as the number of confirmed COVID-19 cases in Korea is around 4,000 every day, the buying trend is concentrated on diagnostic kit stocks. Seegene is trading at 76,100 won, up 5.84% from the previous day, and Lab Genomics at 33,000 won, up 5.1% from the previous day. In addition, Sugentech (6.95%) is showing strength.
Vaccine and treatment-related stocks appear to have fluctuated ups and downs. SK Bioscience soared in the early days of opening and surpassed 300,000 won, but as of 11:28 a.m., it is staying at 274,000 won, down 1.79% from the previous day. SK Bioscience is consigning Novavax’s COVID-19 vaccine and developing its own vaccine. At the same time, Samsung Biologics is trading at 888,000 won, up 2.07%, and Celltrion is trading at 215,000 won, up 0.7%.
Kim Hyung-soo, an analyst at Hanwha Investment & Securities, said, “Labgenomics is a company that is expected to benefit from the advent of ‘Omicron’ and the implementation of ‘With Corona’ in November. .
[이유정 인턴기자]
[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]
